<DOC>
<DOCNO>
EP-0005610
</DOCNO>
<TEXT>
<DATE>
19791128
</DATE>
<IPC-CLASSIFICATIONS>
<main>C07D-403/06</main> C07D-403/00 C07D-405/00 C07D-403/06 C07D-405/12 C07D-405/14 A61K-31/415 
</IPC-CLASSIFICATIONS>
<TITLE>
1-(heterocyclylalkyl)-1,3-dihydro-2h-benzimidazol-2-ones, their preparation, their pharmaceutical compositions and their use as beta-adrenergic receptor blockers.
</TITLE>
<APPLICANT>
janssen pharmaceutica nvbe<sep>janssen pharmaceutica n.v.<sep>janssen pharmaceutica n.v.turnhoutsebaan 30b-2340 beersebe<sep>janssen pharmaceutica n.v.<sep>
</APPLICANT>
<INVENTOR>
kennis ludo<sep>kennis, ludo<sep>kennis, ludoparklaan 5b-2350 vosselaarbe<sep>kennis, ludo<sep>kennis, ludoparklaan 5b-2350 vosselaarbe<sep>
</INVENTOR>
<ABSTRACT>
novel 1-(heterocyclylalkyl)-1, 3-dihydro-2h-benzimidazol-2-ones,  wherein said heterocyclyl group is a  3-pyrrolidinyl or 3-piperidinyl group, each substituted in the  1-position with a 3-aryloxy-2-hydroxypropyl, 3-arylthio-2-hydroxypropyl  or 2-(2, 3-dihydro-1, 4-benzodioxin-2-yl)-2-hydroxyethyl  group, said compounds having useful Î²-adrenergic  receptor blocking activity.  
</ABSTRACT>
</TEXT>
</DOC>
